Summary
Eli Lilly and Company (LLY) filed an 8-K on January 29, 2021, to report its financial results for the fourth quarter and full year ended December 31, 2020. This filing primarily directs investors to an attached press release (Exhibit 99.1) which contains the detailed financial outcomes for the period. Investors should consult this press release for specific figures related to revenue, earnings, and other operational performance metrics. The report itself does not contain the detailed financial statements but serves as the official notification of the release of this information. The press release is expected to provide insights into the company's performance drivers, potentially including contributions from key therapeutic areas and pipeline updates, which are crucial for assessing the company's ongoing business health and future prospects.
Key Highlights
- 18-K filing on January 29, 2021, announcing Q4 and FY 2020 financial results.
- 2Key financial details are provided in the attached press release (Exhibit 99.1).
- 3The press release contains unaudited financial results for the quarter and year ended December 31, 2020.
- 4This filing is furnished under Item 2.02 (Results of Operations and Financial Condition).
- 5Information furnished is not deemed 'filed' for Section 18 purposes, meaning it doesn't trigger liability under that specific section of the Exchange Act.
- 6Exhibit 104 is the Cover Page Interactive Data File in Inline XBRL format.